# Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation

> **NCT01523236** · PHASE1,PHASE2 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 800 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Mometasone furoate
- **DRUG:** Nasonex®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01523236
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2012-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01523236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01523236, "Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01523236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*